How many gene editing drugs are tracked?

Drug Landscape tracks 0 gene editing (0 marketed, 0 Phase 3, 0 Phase 2, 0 Phase 1).

How fresh is this page?

Refreshed every 30 minutes from primary sources (Drugs@FDA, EMA EPAR, ClinicalTrials.gov, sponsor 8-K filings).

Gene Editing — Pipeline, Approvals, Sponsors

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Targeted DNA modification: CRISPR-Cas9, base editing, prime editing. First approval (Casgevy for sickle cell) in 2023; expanding pipeline across hemoglobinopathies, primary hyperoxaluria, transthyretin amyloidosis.

Marketed

Filed

Phase 3

Phase 2

Phase 1

Total

Marketed leaders

No marketed leaders tracked.

Recent approvals (last 30 days)

No approvals in the last 30 days.

Upcoming PDUFA (next 180 days)

No upcoming PDUFA in next 180 days.

Top sponsors in this modality

No sponsor data.

Drug classes within Gene Editing

No class breakdown.

Subscribe to ongoing alerts

Push every new gene editing event into your RSS reader:

Gene Editing firehose — RSS
Recent Gene Editing approvals only
Upcoming Gene Editing PDUFA only

Other modalities

Biologics Monoclonal Antibodies Small Molecules Antibody-Drug Conjugates Cell Therapies Gene Therapies mRNA Therapeutics siRNA Therapeutics Antisense Oligonucleotides Bispecific Antibodies Vaccines

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing